Drugs / rPhleum
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00666341 | Sep 2007 → Jan 2009 | atopic IgE-mediated allergic disorder | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01353755 | Oct 2009 → Aug 2012 | allergic asthma, allergic rhinitis | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rPhleum | “The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities.” NCT01353755 ↗ |
| Known as | recombinant Phleum | “The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities.” NCT01353755 ↗ |
| Modality | Protein / enzyme biologic | “Cocktail of recombinant major allergens of Phleum pratense (timothy grass)” NCT00666341 ↗ |
| Route | Subcutaneous | “The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration.” NCT01353755 ↗ |